Next Article in Journal
Management Effectiveness of a Secondary Coniferous Forest for Landscape Appreciation and Psychological Restoration
Next Article in Special Issue
Smoke-Free Recovery from Trauma Surgery: A Pilot Trial of an Online Smoking Cessation Program for Orthopaedic Trauma Patients
Previous Article in Journal
Physiological Effects of Touching Wood
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessConcept Paper
Int. J. Environ. Res. Public Health 2017, 14(7), 799; https://doi.org/10.3390/ijerph14070799

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke

1
School of Public Health, University of Queensland, Cnr Wyndham Street and Herston Road, Herston, QSD 4006, Australia
2
Lyell McEwin Hospital, University of Adelaide, Haydown Road, Elizabeth Vale, SA 5112, Australia
3
Sexual Health and HIV Service, Metro North Hospital and Health Service, Biala, 270 Roma Street, Brisbane, QSD 4000, Australia
*
Author to whom correspondence should be addressed.
Received: 30 May 2017 / Revised: 5 July 2017 / Accepted: 5 July 2017 / Published: 18 July 2017
(This article belongs to the Special Issue Development and Evaluation of New Tobacco Control Interventions)
Full-Text   |   PDF [431 KB, uploaded 18 July 2017]   |  

Abstract

Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations. View Full-Text
Keywords: smoking; tobacco; HIV; harm reduction; vaporised nicotine; VNPs; e-cigarettes; feasibility smoking; tobacco; HIV; harm reduction; vaporised nicotine; VNPs; e-cigarettes; feasibility
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Bell, S.; Dean, J.; Gilks, C.; Boyd, M.A.; Fitzgerald, L.; Mutch, A.; Baker, P.; Neilsen, G.; Gartner, C.E. Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke. Int. J. Environ. Res. Public Health 2017, 14, 799.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top